Payment overview · 2025
General Payments
$545.17
27 reported records · 10 companies
Healthcare provider profile · identity verified
Jeffrey Basa, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CARSON CITY, NV · NPI 1992851323
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Basa, M.D. received $545.17 in general payments during 2025 across 27 reported records.
ABBVIE INC. accounted for 34.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $189.60 | 34.8% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $72.95 | 13.4% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $65.69 | 12.1% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $58.94 | 10.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.03 | 6.8% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.95 | 6.0% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $28.51 | 5.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.35 | 3.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.05 | 3.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.10 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $545.17 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $189.60 | 12 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $65.69 | 3 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $58.94 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.03 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $32.95 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $28.51 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
97 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 711 | 232 |
| Atorvastatin Calcium | Atorvastatin Calcium | 583 | 211 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 563 | 207 |
| Amlodipine Besylate | Amlodipine Besylate | 412 | 154 |
| Lisinopril | Lisinopril | 351 | 122 |
| Pantoprazole Sodium | Pantoprazole Sodium | 256 | 88 |
| Omeprazole | Omeprazole | 204 | 79 |
| Metformin Hcl | Metformin Hcl | 201 | 76 |
| Losartan Potassium | Losartan Potassium | 188 | 71 |
| Carvedilol | Carvedilol | 176 | 65 |
| Alprazolam | Alprazolam | 160 | 46 |
| Gabapentin | Gabapentin | 160 | 61 |
| Allopurinol | Allopurinol | 149 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 51 |
| Trazodone Hcl | Trazodone Hcl | 144 | 48 |
| Potassium Chloride | Potassium Chloride | 137 | 48 |
| Simvastatin | Simvastatin | 137 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 37 |
| Metformin Hcl Er | Metformin Hcl | 114 | 43 |
| Ozempic | Semaglutide | 109 | 25 |
| Jardiance | Empagliflozin | 106 | 34 |
| Irbesartan | Irbesartan | 98 | 34 |
| Synthroid | Levothyroxine Sodium | 97 | 32 |
| Eliquis | Apixaban | 96 | 33 |
| Montelukast Sodium | Montelukast Sodium | 91 | 32 |
| Estradiol | Estradiol | 85 | 29 |
| Furosemide | Furosemide | 84 | 37 |
| Mounjaro | Tirzepatide | 84 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 23 |
| Lovastatin | Lovastatin | 78 | 29 |
| Ezetimibe | Ezetimibe | 76 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 25 |
| Finasteride | Finasteride | 73 | 29 |
| Glimepiride | Glimepiride | 73 | 26 |
| Raloxifene Hcl | Raloxifene Hcl | 72 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 68 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 26 |
| Meloxicam | Meloxicam | 64 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 20 |
| Clonazepam | Clonazepam | 63 | 12 |
| Fenofibrate | Fenofibrate | 62 | 21 |
| Famotidine | Famotidine | 61 | 22 |
| Tramadol Hcl | Tramadol Hcl | 60 | 21 |
| Benazepril Hcl | Benazepril Hcl | 58 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 56 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 18 |
| Spironolactone | Spironolactone | 52 | 18 |
| Temazepam | Temazepam | 51 | suppressed |
| Valsartan | Valsartan | 48 | 17 |
| Donepezil Hcl | Donepezil Hcl | 47 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 46 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 19 |
| Buspirone Hcl | Buspirone Hcl | 45 | 18 |
| Mirtazapine | Mirtazapine | 45 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 15 |
| Atenolol | Atenolol | 42 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 40 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 39 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 12 |
| Bupropion Xl | Bupropion Hcl | 33 | 12 |
| Acyclovir | Acyclovir | 32 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 32 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 11 |
| Ibuprofen | Ibuprofen | 30 | 11 |
| Armour Thyroid | Thyroid,pork | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 11 |
| Pregabalin | Pregabalin | 29 | 13 |
| Diazepam | Diazepam | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | 13 |
| Fluconazole | Fluconazole | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | 11 |
| Ondansetron Odt | Ondansetron | 21 | 15 |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | 11 |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 17 |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 15 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Yuvafem | Estradiol | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $545.17 · 27 records | ABBVIE INC. | ABRYSVO, BREZTRI, CAPLYTA, COMIRNATY, JOURNAVX, LEQVIO, NEXLETOL, PREVNAR 20, SAPIEN 3 Ultra RESILIA, TRELEGY ELLIPTA, VRAYLAR, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error